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Pharmacokinetic Evaluation of
Empagliflozin in Healthy Egyptian
Volunteers Using LC-MS/MS and
Comparison with Other Ethnic
Populations
Bassam M. Ayoub 1,2, Shereen Mowaka1,2,3, Eman S. Elzanfaly4,5, Nermeen Ashoush2,6,
Mohamed M. Elmazar2,7 & Shaker A. Mousa8
The present study considered the pharmacokinetic evaluation of empagliflozin after administration
to Egyptian volunteers, and the results were compared with other ethnic populations. The FDA
recognizes that standard methods of defining racial subgroups are necessary to compare results across
pharmacokinetic studies and to assess potential subgroup differences. The design of the study was
as an open labeled, randomized, one treatment, one period, single dose pharmacokinetic study. The
main pharmacokinetic parameters estimated were Cmax, Tmax, t1/2, elimination rate constant, AUC0-t
and AUC0-inf. The insignificant difference in pharmacokinetic parameters between Egyptians and white
German subjects suggests that no dose adjustment should be considered with administration of 25 mg
empagliflozin to Egyptian population. A new LC-MS/MS method was developed and validated, allowing
sensitive estimation of empagliflozin (25–600 ng mL−1) in human plasma using dapagliflozin as an
internal standard (IS). The method was applied successfully on the underlying pharmacokinetic study
with enhanced sample preparation that involved liquid-liquid extraction. Multiple Reaction Monitoring
(MRM) of the transition pairs of m/z 449.01 to 371.21 for empagliflozin and m/z 407.00 to 328.81 for
dapagliflozin (IS) was employed utilizing negative mode Electro Spray Ionization (ESI). The validated
LC-MS/MS method is suitable for further toxicodynamic and bioequivalence studies.
The Food and Drug Administration (FDA) defined ethnic factors as those related to races or large populations
grouped according to the International Conference on Harmonization (ICH) guidelines1. Some drugs could be
“ethnically sensitive” according to their metabolic pathways or steep dose-response curves2. The kidney has a
role in the regulation of blood glucose levels and can therefore serve as a target for new anti-diabetic drugs.
Empagliflozin (EG) and dapagliflozin (DG), (Fig. 1), are inhibitors of sodium glucose co-transporter-2 (SGLT-2)
that inhibit glucose re-absorption into the blood3, 4. SGLT-2 is expressed in the kidneys and plays an important
role of renal glucose re-absorption. EG and DG can selectively inhibit SGLT-2 and therefore enhance urinary
glucose excretion. The amount of glucose removed by the kidney through this glucuretic mechanism is dependent
upon the blood glucose concentration and glomerular filtration rate (GFR)3, 4.
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Figure 1. Chemical structures of empagliflozin (a) and the internal standard, dapagliflozin (b).

The pharmacokinetic evaluation of EG after administration to Egyptian volunteers and its comparison to the
previously developed studies on different races will minimize the duplication of clinical data. A fully validated
bioanalytical method is a prerequisite to perform a successful pharmacokinetic study. In the present work, a new
fast LC-MS/MS method was developed for sensitive estimation of EG using DG as an internal standard (IS) to
enable further pharmacokinetic and pharmacodynamic evaluation to facilitate satisfactory clinical outcomes.
LC-MS/MS parameters and analytical procedure details were not described in the pharmacokinetic studies
reported for EG5–23. Chromatograms and parameters of the analytical assay such as chromatographic conditions,
matrix effects, extraction recovery, and stability are not fully described for duplication in most clinical studies5–23.
Therefore, the novelty of the present work was achieved by providing the full details regarding the development
and validation of the proposed analytical procedure for the simultaneous extraction and LC-MS/MS determination of EG and DG (IS). Furthermore, in the present work, the first pharmacokinetic study on healthy Egyptian
volunteers, after administration of 25 mg EG (JARDIANCE), was applicable using the proposed bioanalytical
method.
Investigation of the relationship between drug dosage and the concentration time profiles will be useful for
the design of subsequent clinical trials, appropriate analysis in post-marketing pharmacovigilance, determination of the appropriate use of medicines according to genotype of drug-metabolizing enzymes, and providing
information for therapeutic drug monitoring (TDM). The developed LC-MS/MS method measures the plasma
concentration of the parent compound (EG) because no major metabolites of EG were detected in human plasma
as glucuronidation is the major metabolic pathway14.

Materials and Methods
Instrumentation.

WATERS ACQUITY UPLC system (S/N F08UPH, USA), TQ detector (S/N QBA530,
USA) accompanied with ESI source and WATERS ACQUITY UPLC BEH Shield RP C18 column (S/N
01563430116023, Ireland) with dimensions (150 mm × 2.1 mm, 1.7 µm) were used. MASS LYNX software version 4.1 was used. Vacuum evaporator CHRIST (S/N 20534, Germany), vacuum pump VACWBRAND (DVP2CTYR012, Germany), Vortex VELP SCIENTIFICA (S/N 265349, Europe), −80 °C freezer THERMO SCIENTIFIC
(S/N 836003-375, USA), and Centrifuge HETTICH (S/N 012444807, Germany) were used. Validated Excel software was used to calculate the pharmacokinetic parameters.

Chemicals, reagents, stock solutions and working solutions.

Pharmaceutical grade EG certified to
contain 99.90%, JARDIANCE tablets nominally containing 25 mg of EG per tablet, was supplied from Boehringer
Ingelheim pharmaceutical company (Germany). Pharmaceutical grade DG certified to contain 99.80% was kindly
donated by researcher Moataz Hendy, research assistant at the Center for Drug Research and Development
funded by the British University in Egypt (CDRD, BUE). Human plasma was donated from Vacsera (Egypt).
Ammonium acetate, tert-butyl methyl ether (TBME), formic acid, deionized water, and HPLC grade acetonitrile
were purchased from Sigma Aldrich (USA). Stock solutions of pharmaceutical grade EG (1 mg/mL) and DG
(1 mg/mL) were prepared separately in acetonitrile. Working solutions of EG (50 µg/mL) and DG (1 µg/mL) were
prepared separately in acetonitrile with appropriate dilutions from stock solutions. All solutions were stored at
4 °C.

Chromatographic and mass spectrometric conditions.

A mixture of deionized water and acetonitrile
in the ratio of (10:90, v/v) was used as the mobile phase. The column temperature was kept at 25 °C, the injection
volume used was 10 µL, and the flow rate was 0.3 mL/min with 1.5 min as the run time. Cone voltage was set at
40 V; source temperature was set at 150 °C, and the collision energy was set at 30 eV for both drugs to enable multiple reaction monitoring (MRM) of the transition pairs of m/z 449.01 to 371.21 for EG and m/z 407.00 to 328.81
for DG (IS) in the negative mode utilizing Electro Spray Ionization (ESI). The following parameters were applied:
turbo ions spray at 400 °C, capillary temperature at 275 °C, sheath and auxiliary gas at 15 and 2 psi, respectively,
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ion spray voltage of 3800 V, capillary voltage of 4 KV, capillary offset of 35 and de-solvating line temperature at
400 °C.

Procedures and method validation. Sample preparation, calibrators (linearity,) and QC samples (accuracy

and precision). Each EG calibrator and quality control (QC) plasma sample (980 µL) was spiked with 20 µL containing the appropriate amount of EG in acetonitrile prepared with dilution of EG working solution. All samples
including the volunteers’ plasma samples (1 mL plasma) were spiked with 100 µL of IS that contained 100 ng of
DG followed by vortexing for 20 sec. Five milliliters of TBME were added, vortexed for 1 min, and centrifuged
for 30 min at 6000 rpm. Four milliliters of the organic layer were vacuum evaporated until dryness at 60 °C. Three
hundred microliters of acetonitrile were added to reconstitute the resulting residue and vortexed for 3 min. Ten
microliters of the reconstituted solution were injected into the LC-MS/MS system.
Different EG concentrations equivalent to (25, 100, 200, 300, 400, 600 ng) per 20 µL were prepared in acetonitrile using appropriate volumes of working solutions. Plasma samples were prepared by spiking 980 µL human
plasma with 20 µL of EG and finally spiked with 100 µL of IS working solution in acetonitrile (1 µg/mL). After the
sample preparation, the peak area ratios of EG to IS against the corresponding concentrations of 25–600 ng/mL
for EG were used to generate the calibration curve. Both plasma standards and QC samples were kept at −80 °C
until used.
Different EG concentrations in acetonitrile were used to prepare different QC levels: lower as 50 ng/mL (LQC),
middle as 250 ng/mL (MQC), and high as 500 ng/mL (HQC). Then the procedure was repeated to check the accuracy of the results along with lower limit of quantification (LLOQ). Repeatability was assessed with the analysis of
replicates of QC samples and LLOQ on the same day (n = 6), while the intermediate precision was assessed with
their analysis on three successive days.
Selectivity, matrix factor, and recovery. Selectivity of the method was assessed by analyzing 6 different blank
plasma samples obtained from different sources. The matrix factor was determined by measuring the peak areas
of EG from the post-extracted LQC and HQC samples and its comparison to the peak areas of neat samples at
the same concentrations in acetonitrile to estimate the effect of the biological matrix on the ionization of EG. The
extraction recovery was determined by measuring the peak areas of EG from LQC and HQC samples extracted
from human plasma followed by its comparison to the peak areas of the same QC samples prepared by spiking the
supernatant of the extracted blank plasma.
Carry-over and stability experiments. Carry-over effect was assessed by injecting blank samples after HQC to
ensure that its response was less than 20% of the LLOQ. Aliquots of LQC and HQC samples were kept for a period
of 6 hrs at room temperature to check short-term stability. The post-operative stability of the processed samples
was examined by keeping LQC and HQC samples in the auto sampler at 25 °C for 24 hrs. Long-term stability was
determined by storing aliquots of LQC and HQC samples at −80 °C for 1 week. The stability of the analytes was
determined after freeze and thaw cycles, using aliquots of LQC and HQC samples stored at −80 °C for 24 hrs and
thawed unassisted at room temperature. Evaluation of stability was carried out by comparing the mean recovery
of EG and IS obtained from stored samples with the mean values obtained using freshly prepared samples at the
same concentration levels; the concentration change should be less than 15% of the nominal concentration24.
Human subjects and pharmacokinetic study of EG. The pharmacokinetic parameters of EG were studied
in healthy human subjects according to the ethical regulations of World Medical Association Declaration of
Helsinki (October 1996) and the International Conference of Harmonization Tripartite Guideline for Good
Clinical Practice. Written informed consent was provided by each volunteer before enrollment. Approval of the
study by the ethical committee was mandatory according to the Egyptian ministry of Health and The British
University in Egypt research ethics guidelines. The experimental protocols were approved by the ethics committee of the Faculty of Pharmacy, The British University in Egypt. The clinical trial protocol was registered in a
publically accessible primary register that participates in the WHO International Clinical Trial Registry Platform
(ClinicalTrials.gov, 16/02/2017, ID: NCT03059056). Good health of the human subjects was confirmed with a
complete medical history and physical examination. Fasting of all volunteers eliminated the possible interaction
from high fat meals. The evaluation of safety of the study was based on monitoring of blood glucose level, vital
signs, pulse rate, monitoring of adverse events, and physical examination. Samples from 6 healthy, adult, male,
Egyptian volunteers (age: 22–33 years, average weight: 77.8 kg, average body mass index (BMI): 29.2) were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one JARDIANCE tablet nominally containing 25 mg EG.
Blood samples (3 mL of each sample) were centrifuged at 3000 rpm for 5 min, 1 mL of the plasma was separated
and spiked with 100 µL (equivalent to 100 ng) of IS working solution, and then the procedure discussed under
(Sample preparation) was applied. The main pharmacokinetic parameters of the study, Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf, were estimated using validated Excel software. Blood glucose level was
determined for all volunteers at 0 and 1.5 hrs to monitor any hypoglycemic effect. The study was conducted as
per FDA guidelines.

Results and Discussion

Optimization of sample preparation, chromatographic conditions, and mass spectrometric
parameters. The LC-ESI-MS/MS method was developed for accurate and sensitive estimation of EG in

human plasma. For the extraction procedure, liquid-liquid extraction was tried using ethyl acetate, dichloromethane, and diethyl ether, and the best results were obtained with TBME. This may be attributed to the ability of EG
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Figure 2. Full scan mass spectrum (a) and daughter ion mass spectrum (b) of empagliflozin in negative ESI ion
detection mode with the proposed fragment.

and DG (IS) to migrate to TBME according to their partition coefficients and log P values. Using DG as IS for EG
bioanalysis enhanced the validation results because of their structural similarity (Fig. 1), closely related plasma
extraction recoveries, and similar matrix factors (MF). After vortex and centrifugation, vacuum evaporation of
the TBME layer until dryness at 60 °C followed by reconstitution with 300 µL acetonitrile was employed as a sample enrichment technique, enabling determination of EG at the LLOQ, equal to 25 ng/mL. Another advantage of
using liquid extraction is sample clean-up, decreasing the matrix effect on the detector response. Furthermore,
using acetonitrile as solvent for IS decreased the formation of irregular emulsion between aqueous/organic interfaces and modulated the polarity of the extraction solvents to achieve the desired recovery25. In addition, TBME
was reported by Kobuchi et al. for sample preparation of some SGLT-2 inhibitors26–29 with structural similarity to
EG, namely, canagliflozin26, tofogliflozin27, ipragliflozin28, and luseogliflozin29 using EG26–28 or DG29 as IS.
For optimum detection of EG and the IS, both the chromatographic conditions and the mass detector parameters were adjusted. Both positive and negative ionization modes and various mobile phases (containing ammonium acetate or formate) were initially assessed. Although LC-MS/MS in the positive mode ESI has been reported
in literature while using EG as IS26–28, the best intensities for precursor and product ions were attained in the
negative mode for EG and the IS (Figs 2 and 3); this may be attributed to the reported adduct formation in the
case of using positive mode with EG or DG29, 30. Also a study published by Iqbal et al.31 recommended the use of
negative mode over the positive mode for superior sensitivity advantages for canagliflozin.
Molecular ions of 449.01 and 407.00 were observed for EG and DG, respectively, on the full scan mass spectra (Figs 2 and 3). The optimized collision energy produced significant fragments. The MS/MS transition of
449.01 → 371.21 and 407.00 → 328.81 for EG and the IS, respectively, were selected. The selected DG transition
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Figure 3. Full scan mass spectrum (a) and daughter ion mass spectrum (b) of dapagliflozin in negative ESI ion
detection mode with the proposed fragment.

is consistent with previous LC-MS/MS methods in the negative mode29, 30, while the transition of EG is reported
here for the first time using negative mode. Both EG and DG fragments can be explained as shown in Figs 2 and 3.
To attain the optimum chromatographic conditions, various combinations of organic solvents and different
concentrations of formic acid solution were tried for the positive mode trials, while different concentrations
of ammonium acetate buffer and different acetonitrile/water ratios were tried for the negative mode. The final
mobile phase was selected based on the high response and best peak shape of the analytes in a reasonable run
time. Because DG (IS) readily forms adducts in the presence of formic acid, the mobile phases were simple mixtures of water and acetonitrile, which is consistent with previous reports for LC-MS/MS determination of DG30.
Optimum results with well-defined peaks and high sensitivity (Figs 4 and 5) were obtained using a mixture of
water and acetonitrile in the ratio of (10:90, v/v) as a mobile phase, keeping column temperature at 25 °C, using
10 µL as the injection volume and 0.3 ml/min as the flow rate with 1.5 min as run time. LC-MS/MS was selected
for the underlying investigation because it is a well-known, sensitive technique that has been commonly used for
many pharmacokinetic studies32–37.

LC-MS/MS method validation.

Linearity, accuracy, and precision. The plasma calibration curves were
constructed by plotting the (drug/IS) peak area ratios of 6 samples against EG concentrations covering the
expected range including LLOQ (FDA, 2001)24. The regression equation was found to be (peak area ratio = 0.0106
concentration + 0.0634) with correlation coefficient (r) = 0.9997. The lowest concentration at S/N ratios of 10
with the %RSD <20% was taken as LLOQ (25 ng/mL). The results were in agreement with FDA recommendations24 that the correlation coefficient (r) of a calibration curve should be less than 0.99, and the deviation of the
back-calculated concentrations at each point was found to be within ±15% and within ±20% for the LLOQ.
Accuracy was measured by repeated analysis of each drug in human plasma. LLOQ and three concentration
levels were studied as low, medium, and high QC (FDA, 2001)24. The mean value was within 15% of the actual
Scientific Reports | 7: 2583 | DOI:10.1038/s41598-017-02895-7
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Figure 4. Multiple reaction monitoring (MRM) chromatogram of empagliflozin (m/z = 449.01 to 371.21) and
dapagliflozin (internal standard, m/z = 407.00 to 328.81): (a) blank plasma; (b) zero plasma spiked with internal
standard.

values for LLOQ and the QC samples ranged from 98.46% to 101.19%, showing that the bias% ranged from −1.54
to 0.19, confirming the accuracy of the proposed method. The precision, percent coefficient of variation (% C.V.),
was within 15% of the actual values. The intra-day and inter-day precision values confirmed that the proposed
methods are precise, with %RSD ranging from 4.71% to 6.99%.
Selectivity, matrix factor, and recovery. Selectivity and lack of interference from plasma components was confirmed by comparison between blank plasma and spiked plasma chromatograms at LLOQ of both EG and IS.
Matrix factor (MF) describes the analyte ionization efficiency in the ion source due to co-eluting matrix components. MF for EG ranged from 0.90 (HQC) to 0.88 (LQC), indicating no significant matrix effect over the ionization of EG. Recovery describes the efficiency of separating the drug from the sample. Recovery experiments were
performed by comparing the peak area of the low and high QC samples extracted from human plasma with those
spiked in the supernatant of the extracted blank plasma at the same concentration levels. The average recoveries
of EG were 77.19% for the LQC and 83.84% for HQC samples, which satisfy the FDA recommendation of being
above 70%.
Carry-over and stability experiments. Carry-over effect was addressed during method development by injecting
blank samples after HQC sample, i.e. 500 ng/mL of EG and checking the response of EG (peak area). Carry-over
in the blank sample following the high concentration standard was <20% of the LLOQ, as recommended by
FDA24. Stability experiments were performed using 2 concentrations (low and high QC), and the results are
acceptable because the concentration change was <15% of the actual values, confirming that the processed samples were stable while studying short-term stability, freeze-thaw stability, post-operative stability, and long-term
stability.
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Figure 5. Multiple reaction monitoring (MRM) chromatogram of empagliflozin (m/z = 449.01 to 371.21) and
dapagliflozin (internal standard, m/z = 407.00 to 328.81): (a) lower limit of quantitation (LLOQ); (b) human
plasma sample obtained 1.5 hrs after oral administration of one JARDIANCE tablet nominally containing 25 mg
of empagliflozin.

Pharmacokinetic evaluation of EG.

Development of correlations between drug concentrations and
their pharmacologic responses enable clinicians to apply pharmacokinetic principles to actual patient situations.
Pharmacokinetic studies are necessary for the submission of a new drug application (NDA) to the FDA and for
re-examination of approved drugs. For extrapolation of clinical data from other countries, ethnic differences in
pharmacokinetics must be discussed.
The proposed method was applied to a pharmacokinetic study and the mean plasma concentration (nMol/L)
was plotted against time (Fig. 6). The main pharmacokinetic parameters of the study are presented in Table 1. Cmax
and Tmax values suggest that EG is rapidly absorbed from the gastrointestinal tract into the circulation.
No clinically meaningful interactions were observed when EG was co-administered with other commonly
used medicinal products and no dose adjustment was recommended5–23. The insulin-independent mechanism of
action of EG contributes to a low risk of hypoglycemia that was proved by monitoring of blood glucose level of all
volunteers while carrying out the study, and the results were in the normal range. The glucosuria observed with
EG was accompanied by mild diuresis.
The previous pharmacokinetic studies confirmed the absence of pharmacokinetic interaction of EG with pioglitazone8, hydrochlorothiazide10, torasemide10, gemfibrozil15, rifampicin15, probenecid15, linagliptin21, or sitagliptin22. In addition, pharmacokinetic parameters were checked in special populations with heart failure5, renal
impairment11, 12, or hepatic impairment14 with no need for dose adjustment. Furthermore, efficacy6, tolerability18–20, single dose and multiple dose kinetics7, 9 were reported. The present study compared the pharmacokinetic parameters of Egyptian volunteers to previously reported non-Egyptian populations using 25 mg EG. The
calculated pharmacokinetic parameters were closely related to previous studies conducted in white German subjects using 25 mg EG. The insignificant difference in ANOVA statistical results (Table 2) of the pharmacokinetic
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Figure 6. The mean plasma concentration-time curves of empagliflozin after oral administration of one
JARDIANCE tablet nominally containing 25 mg of empagliflozin. Each symbol with a bar represents the
mean ± S.D. of 6 subjects.

Pharmacokinetic parameters

Empagliflozin

Cmax (nMol/L), Mean ± S.D. (% C.V.)

576 ± 86 (14.93)

Tmax (hours), Median (range)

1.5, (1–2)

t 1/2 (hours), Mean ± S.D. (% C.V.)

6.1 ± 1.2 (19.67)

Elimination rate constant (h−1),
Mean ± S.D. (% C.V.)

0.10012 ± 0.02156 (19.25)

AUC0−t (12) (nMol.h/L), Mean ± S.D.
(% C.V.)

2806 ± 234 (8.34)

AUC0-inf (nMol.h/L), Mean ± S.D.
(% C.V.)

4103 ± 427 (10.41)

Table 1. Pharmacokinetic parameters of empagliflozin (EG) following oral administration of one JARDIANCE
tablet nominally containing 25 mg of EG. Abbreviations: AUC = area under the curve; % C.V. = percent
coefficient of variation; S.D. = standard deviation.
Cmax (nMol/L)

AUC0-inf (nMol.h/L)

*Groups

Number of
subjects

Mean

S.D., (% C.V.)

Mean

S.D., (% C.V.)

Group 113, 38

6

505

130, (25.74)

3830

825, (21.54)

Group 215

18

610

98.82, (16.20)

4770

797, (16.7)

Group 320

9

606

147, (24.26)

4310

1040, (24.13)

Group 420

9

630

106, (16.83)

4990

1080, (21.64)

Egyptian subjects

6

576

86, (14.93)

4103

427, (10.41)

Table 2. One way ANOVA results at P < 0.05 for Cmax and AUC 0-inf after administration of 25 mg empagliflozin
in German and Egyptian subjects. *Studied groups from pharmacokinetic studies conducted in white German
subjects using 25 mg EG13, 15, 20, 38 showed no significant difference at P > 0.05, with P = 0.283 for Cmax and
P = 0.064 for AUC0-inf. Abbreviations: AUC = area under the curve; % C.V. = percent coefficient of variation;
S.D. = standard deviation.
evaluation in Egyptians and white German subjects13, 15, 20, 38 suggests that no dose adjustment should be considered with administration of 25 mg EG to Egyptian population.
The insignificant difference between Japanese and Chinese populations (Table 3) may be attributed to the similarity in their BMI as Asian race. A significant difference was observed (Table 4) when comparing all races (white
German, Egyptian, Japanese, and Chinese), which may be attributed to the difference in weight and BMI between
races that was confirmed in a previous EG population study17 that mainly reported the ethnic difference between
white and Asian races but did not consider the Egyptian population, which was proved to be similar to the white
German volunteers. The reported population study17 included different BMI values for the ethnic groups, which
was found to be 31.4 kg/m2 for the white population and 24.6 kg/m2 for the Asian population.

Conclusion

Pharmacokinetic parameters can vary between different races, and the present analysis was the first study carried
out on Egyptian volunteers and compared with the results obtained from other ethnic populations. There is no
significant difference was observed between the studied group and the compared ethnic group which suggests
that no dose adjustment should be considered with administration of 25 mg EG to Egyptian population. The proposed LC-MS/MS method is simple, fast, accurate, and reproducible for determination of EG in human plasma.

Scientific Reports | 7: 2583 | DOI:10.1038/s41598-017-02895-7

8

www.nature.com/scientificreports/
Cmax (nMol/L)

AUC0-inf (nMol.h/L)

Groups

Number of
subjects

Mean

S.D., (% CV)

Mean

S.D., (% CV)

*Group 111

8

1070

193.7, (18.1)

7560

1126.4, (14.9)

*Group 29

9

1130

318.7, (28.2)

7450

1959, (26.3)

Table 3. One way ANOVA results at P < 0.05 for Cmax and AUC0-inf after administration of 25 mg empagliflozin
in Japanese11 and Chinese subjects9. *Studied groups from pharmacokinetic studies conducted in Japanese11
and Chinese9 subjects using 25 mg empagliflozin showed no significant difference at P > 0.05, with P = 0.651 for
Cmax and P = 0.891 for AUC0-inf. Abbreviations: AUC = area under the curve; % C.V. = percent coefficient of
variation; S.D. = standard deviation.

Parameter

F

P

Cmax (nMol/L)

19.614

0

AUC0-inf (nMol.h/L)

15.796

0

Table 4. One way ANOVA results at P < 0.05 for Cmax and AUC0-inf after administration of 25 mg empagliflozin
in German13, 15, 20, 38, Japanese11, and Chinese subjects9. F-test is a statistical test in which the test statistic has
an F-distribution under the null hypothesis; P is the probability using a given statistical model using ANOVA.
Abbreviations: AUC = area under the curve.
The validated method was proved to be suitable for further toxicodynamic evaluation. The method was applied
successfully for the pharmacokinetic study under investigation and owing to the short run time used, rapid analysis of many plasma samples per day was achieved.
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